Abivax S.A.
ABVX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001956827
No open-market purchases or sales by Abivax S.A. insiders were filed in the last 90 days; 318 institutions reported holding it in 13F filings for Q3 2026, worth $5.64B in total; no superinvestor holds it.
Other share classesAAVXF
- Currency
- EUR
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 3:06 PM ET
Amounts are in EUR, the currency Abivax S.A. reports in. Lines marked ≈ US$ convert key figures to US dollars.
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: EUR 336.1M (7354.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 20-F | 20-F | 20-F |
| Reported | – | – | – |
| Revenue | EUR 4.57M≈ US$5.17M | EUR 12.4M≈ US$13.5M | EUR 4.62M≈ US$5.00M |
| Operating expenses | EUR 250.6M | EUR 185.4M | EUR 132.0M |
| Research and development | EUR 177.8M | EUR 146.5M | EUR 103.2M |
| Selling, general and administrative | EUR 67.7M | EUR 32.9M | EUR 22.4M |
| Operating income | EUR -246.1M | EUR -173.0M | EUR -127.4M |
| Interest expense | EUR 111.7M | EUR 17.0M | EUR 27.9M |
| Income tax | EUR 5.85M | EUR 0 | EUR 0 |
| Net income | EUR -336.1M≈ US-$380.0M | EUR -176.2M≈ US-$190.7M | EUR -147.7M≈ US-$159.8M |
| EPS, basic | EUR -4.83 | EUR -2.80 | EUR -3.43 |
| EPS, diluted | EUR -4.83 | EUR -2.80 | EUR -3.43 |
| Weighted shares, basic | 69.5M | 63.0M | 43.1M |
| Weighted shares, diluted | 69.5M | 63.0M | 43.1M |
| Margins and growth | |||
| Operating margin | -5384.2% | -1389.5% | -2756.5% |
| Net margin | -7354.5% | -1415.7% | -3197.1% |
| Revenue growth, year over year | −63.3% | +169.4% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 20-F | 20-F | 20-F |
| Reported | – | – | – |
| Cash and equivalents | EUR 516.7M | EUR 144.2M | EUR 251.9M |
| Total current assets | EUR 551.2M | EUR 170.7M | EUR 286.0M |
| Goodwill | EUR 18.4M | EUR 18.4M | EUR 18.4M |
| Intangible assets | EUR 6.61M | EUR 6.61M | EUR 6.60M |
| Total assets | EUR 584.3M≈ US$685.8M | EUR 205.2M≈ US$212.4M | EUR 327.1M≈ US$361.8M |
| Accounts payable | EUR 37.6M | EUR 43.8M | EUR 47.2M |
| Total current liabilities | EUR 63.0M | EUR 94.0M | EUR 70.0M |
| Shareholders' equity | EUR 455.2M | EUR 40.6M | EUR 196.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 20-F | 20-F | 20-F |
| Reported | – | – | – |
| Operating cash flow | EUR -161.1M≈ US-$182.2M | EUR -154.1M≈ US-$166.7M | EUR -97.1M≈ US-$105.1M |
| Capital expenditures | EUR 142.0K | EUR 640.0K | EUR 265.0K |
| Free cash flow | EUR -161.3M≈ US-$182.3M | EUR -154.7M≈ US-$167.4M | EUR -97.4M≈ US-$105.3M |
| Stock-based compensation | EUR 35.4M | EUR 20.2M | EUR 8.18M |
| Investing cash flow | EUR -8.19M | EUR 15.8M | EUR -8.10M |
| Financing cash flow | EUR 547.3M | EUR 28.2M | EUR 335.3M |
| Net change in cash | EUR 372.5M | EUR -107.7M | EUR 225.0M |
| Ratio | |||
| Stock-based compensation, % of revenue | 774.6% | 162.5% | 177.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- ≈ US$ figures convert EUR at FRED H.10 exchange rates (Federal Reserve): the average rate over the period for income and cash flow, and the rate on the period-end date, or the last business day before it, for the balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.